Comparative Pharmacology
Head-to-head clinical analysis: KOGLUCOID versus PALYNZIQ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KOGLUCOID versus PALYNZIQ.
KOGLUCOID vs PALYNZIQ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
KOGLUCOID (velaglucerase alfa) is a recombinant form of human glucocerebrosidase, which catalyzes the hydrolysis of glucocerebroside to glucose and ceramide. It replaces the deficient enzyme in patients with Gaucher disease, reducing accumulation of glucocerebroside in macrophages.
PALYNZIQ (pegvaliase-pqpz) is a recombinant phenylalanine ammonia lyase conjugated to polyethylene glycol. It converts phenylalanine to trans-cinnamic acid and ammonia, reducing blood phenylalanine levels in patients with phenylketonuria.
60 U/kg intravenously over 4 hours every 2 weeks.
2.4 mg subcutaneously once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 15-30 minutes (range 11-35 min) in plasma after IV infusion. Short half-life necessitates frequent dosing (every 2 weeks). This reflects rapid clearance via receptor-mediated uptake into macrophages.
Approximately 60–80 hours (terminal half-life); supports weekly dosing regimen.
KOGLUCOID (velaglucerase alfa) is a recombinant human glucocerebrosidase used for Gaucher disease. It is a protein therapeutic; elimination occurs via catabolism (proteolysis) to small peptides and amino acids. No significant renal or biliary excretion of intact drug. <1% excreted unchanged in urine.
Renal (predominantly as intact pegylated enzyme); less than 5% fecal. No active metabolites.
Category C
Category C
Enzyme Replacement Therapy
Enzyme Replacement Therapy